TICKERNERD
Menu
BCTXBCTXHealthcare · Biotechnology

BCTX Stock Forecast: BriaCell Therapeutics Corp. Price Predictions for 2026-2027

Last close, 9 Oct 2026
$3.91

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 9 Oct 2026 — in the weakest quartile.

Market cap
$29.4M
Ticker Nerd rank
8/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$7.6M
Net income−$7.2M
Free cash flow−$7.1M
Quarterly, 8 quarters to 30 Apr 2026 · latest quarter's figure shown
Ticker Nerd rank

BCTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BriaCell Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 9 Oct 2026
8/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Volatility
31
Growth
28
Accruals
28
Revisions
25
Value
24
Issuance
23
Quality
17
Momentum
8

Size (85): Smaller than most of the companies we track.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCTX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2025HC Wainwright & Co.MaintainsBuy$32 → $40
22 Apr 2025HC Wainwright & Co.ReiteratesBuy—
3 Feb 2025HC Wainwright & Co.MaintainsBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2024HC Wainwright & Co.MaintainsBuy—
11 Sept 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Dec 2023HC Wainwright & Co.ReiteratesBuy$18
3 Oct 2023HC Wainwright & Co.MaintainsBuy$25 → $20
28 June 2023HC Wainwright & Co.ReiteratesBuy$25
24 Feb 2023HC Wainwright & Co.ReiteratesBuy$25
14 Feb 2022HC Wainwright & Co.InitiatesBuy$25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BCTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Estimates

BCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

BriaCell Therapeutics Corp. (BCTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 69% of US stocks

EV / EBITDA
−0.2×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−175.3%

Higher than 8% of US stocks

Return on assets
−90.8%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BriaCell Therapeutics Corp. (BCTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BriaCell Therapeutics Corp. has a market value of $29.4M and an enterprise value of $6.0M.

  • Revenue in the twelve months to 30 Apr 2026: $0.0.

  • Net income over the same four quarters: −$29.0M.

  • Diluted earnings per share, trailing twelve months: $−24.32.

  • Free cash flow in the twelve months to 30 Apr 2026: −$30.0M.

  • Shares outstanding: 7.3M.

  • Trailing P/E: −0.1×; forward P/E: −9.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • BriaCell Therapeutics Corp. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 20 Oct 2026

Data provided by Twelve Data

Peers

BCTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BCTXBriaCell Therapeutics Corp.$29.4M8
IRLAIRulya Therapeutics, Inc.$33.7M34
NNVCNanoViricides, Inc.$33.0M60
FLNAFilana Therapeutics, Inc.$32.9M66
CRVOCervoMed, Inc.$34.9M33
LITSLite Strategy, Inc.$35.3M29
EYPTEyePoint, Inc.$36.4M10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BriaCell Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCTX news & analysis

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

GlobeNewsWire · 6 Oct 2026positive

BriaCell and majority-owned subsidiary BriaPro said four abstracts featuring preclinical research from their immunotherapy programs were selected for poster presentations at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix. Topics include BriaCell’s Bria-OTS+ and BriaPro’s soluble CD80 (BP-80), tumor-targeted checkpoint inhibitors and engineered CD80 variants.

Why it matters — The presentations will highlight preclinical research from BriaCell and BriaPro’s immunotherapy programs at a major immunotherapy meeting.

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

GlobeNewsWire · 14 Sept 2026positive

BriaCell Therapeutics announced that the independent Data Safety Monitoring Board (DSMB) issued its seventh consecutive positive recommendation to continue the pivotal Phase 3 Bria-ABC study, which evaluates Bria-IMT plus an immune checkpoint inhibitor in patients with metastatic breast cancer (NCT06072612).

Why it matters — A seventh consecutive positive DSMB recommendation signals continued safety and clinical progress in BriaCell's lead Phase 3 program, encouraging for investors tracking the study's advancement.

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

GlobeNewsWire · 8 Sept 2026positive

BriaCell Therapeutics announced that Memorial Sloan Kettering Cancer Center has joined its ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer. The study is listed under ClinicalTrials.gov identifier NCT06072612.

Why it matters — Adding a leading cancer center to the pivotal Phase 3 study expands patient access and underscores institutional validation of BriaCell's immunotherapy trial.

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

GlobeNewsWire · 24 Aug 2026positive

BriaCell announced that its personalized whole cell melanoma immunotherapy vaccine candidate, Bria-MEL+, has achieved a key genetic engineering milestone, advancing the program toward clinical development. The candidate is designed to harness patients' own immune systems against melanoma and expands on the company's therapeutic vaccine platform developed in metastatic breast and prostate cancer.

Why it matters — The milestone advances Bria-MEL+ toward clinical development, broadening BriaCell's therapeutic vaccine pipeline beyond its existing breast and prostate cancer programs.

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

GlobeNewsWire · 5 Aug 2026positive

BriaCell announced that the FDA completed its review of the Investigational New Drug application for Bria-PROS+, issuing a Study May Proceed letter and clearing the way for a Phase 1/2a clinical study in prostate cancer. Bria-PROS+ is the company's next-generation personalized, off-the-shelf, cell-based immunotherapy, which had previously received a $2 million grant from the US National Cancer Institute.

Why it matters — FDA clearance of the IND allows BriaCell to move Bria-PROS+ into clinical evaluation in prostate cancer, a key milestone in advancing its oncology pipeline.

FAQ

Frequently asked questions about BCTX stock

Is BCTX stock a buy right now?

Of the 1 analysts covering BriaCell Therapeutics Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BriaCell Therapeutics Corp. 8 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCTX?

As at 9 Oct 2026, BriaCell Therapeutics Corp. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

What is the BCTX stock forecast for 2030?

No analyst covering BriaCell Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCTX are extrapolating price history, which says nothing about the business.

What does BriaCell Therapeutics Corp. do?

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer.

What is the latest news on BCTX?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting". BriaCell and majority-owned subsidiary BriaPro said four abstracts featuring preclinical research from their immunotherapy programs were selected for poster presentations at the SITC 2026 Annual Meeting, scheduled for November 4–8 in Phoenix. Topics include BriaCell’s Bria-OTS+ and BriaPro’s soluble CD80 (BP-80), tumor-targeted checkpoint inhibitors and engineered CD80 variants.

Company

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. BriaCell Therapeutics Corp. is best known for its cell-based oncology programs, including Bria-IMT, a lead therapy being studied for metastatic breast cancer, along with Bria-OTS, a personalized off-the-shelf immunotherapy platform, and Bria-PROS+ for prostate cancer. The company also works on BriaDx, a diagnostic tool designed to support patient selection for its immunotherapy approaches. Its current business centers on advancing cancer treatment candidates through clinical development, with an emphasis on breast cancer and other solid tumors. Based in West Vancouver, Canada, BriaCell Therapeutics Corp. operates within the immuno-oncology segment of the healthcare market, where it develops novel therapeutic and diagnostic assets aimed at improving how cancer is detected and treated.

CEO Dr. William V. Williams FCPA, M.D. · 16 employees · Canada · https://briacell.com